Do you want to read an article? Please log in or register.
Survival outcomes and treatment patterns in myelofibrosis in the JAK inhibitor era
Myeloproliferative Neoplasms (MPNs)
Related content
Myeloproliferative Neoplasms (MPNs)
Ruxolitinib treatment for myelofibrosis with anemia: a retrospective assessment of real-world patient characteristics, treatment patterns, and survival
Leuk Lymphoma
Kuykendall AT, Palandri F, Fillbrunn M, Liu T, Zhang S, Zhang A, Simpson R, Sajeev G, Signorovitch J, Patnaik D, Gerds AT
doi: 10.1080/10428194.2026.2628361
Multiple Myeloma (MM)
Real-world treatment patterns and clinical outcomes among patients with relapsed/refractory multiple myeloma initiating their second, third, and fourth lines of treatment: data from the US Flatiron database
Leuk Lymphoma
Nieto MJ, Shih YH, Fang J, Qiu Y, Gentili C, Hernandez Rivera G
doi: 10.1080/10428194.2026.2702128
Lung, Respiratory and Thoracic CancerCOVID-19
Real-world treatment sequencing and survival in ROS1-Rearranged NSCLC across evolving treatment eras: Findings from the AURORA multi-centre registry (AURORA-ROS1)
Lung Cancer
Itchins M, Alexander M, Kao S, Nagrial A, Brown LJ, Bowyer S, Parakh S, Moore M, Kong BY, Yeo N, Hughes BGM, Arulananda S, Chin V, Warburton L, Khoo T, Mersiades AJ, Leigh L, Rogers J, Pavlakis N, Solomon BJ
doi: 10.1016/j.lungcan.2026.109500
EHA 2026
Myeloproliferative Neoplasms (MPNs)
LB5002: SENTRY: The addition of selinexor to ruxolitinib significantly improves spleen volume reduction in patients with JAK inhibitor-naïve myelofibrosis
Non-Malignant Blood Disorders
Real-world treatment patterns and outcomes among patients with immune thrombocytopenia (ITP) who switched treatment from eltrombopag or romiplostim to avatrombopag in the United States: Results from the REAL-AVA 3.5 study
Br J Haematol
Piatek C, Oladapo A, Kolodny S, Vredenburg M, Lucht S, Bland E, Pathak P, Feinberg B, Maitland H
doi: 10.1111/bjh.70531
Multiple Myeloma (MM)
Survival Outcomes with Cilta-cel Versus Conventional Treatment Regimens for Patients with Lenalidomide-Refractory Multiple Myeloma Using Inverse Probability of Treatment Weighting
Adv Ther
Fonseca R, Diels J, Ghilotti F, Mendes J, Van Hoorenbeeck S, Lee S, Schecter JM, Lendvai N, Patel N, Triguero A, Alsdorf W, van de Donk NWCJ, Ursi M
doi: 10.1007/s12325-025-03278-5
Lung, Respiratory and Thoracic Cancer
Real-World Treatment Patterns and Clinical Outcomes in Patients With Extensive-Stage Small Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy and ≥ 2 Subsequent Lines of Therapy in the United States
Adv Ther
Sankar K, Unni S, Eberl M, Le H, Herrmann T, Gorsh B, Tang M, Coerts F, Ahmed S
doi: 10.1007/s12325-025-03408-z
COMMENTED
Lung, Respiratory and Thoracic Cancer
Real-World Treatment Patterns and Survival in Patients with ROS1-Positive Advanced Non-Small Cell Lung Cancer in Canada and Europe
★ 1
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 3
Recommended and commented by
Dr Marcus Hesse, Faculty Member
Curr Oncol
Cheung WY, Lee A, Bote de Cabo H, Burdenski K, Christopoulos P, Pinto-Correia B, Deshayes S, Girard N, Hindocha P, Madden Á, Mella M, Moreira J, Rizzi S, Abreu DR, Soares M, Thomas J, Han M, Calvet CY, Emanuel G, Glassberg MB, Jacobs H, Rault C, Yuan Y, Chouaid C
doi: 10.3390/curroncol33030152
Lung, Respiratory and Thoracic Cancer
Mutation testing, treatment patterns, and outcomes in patients with unresectable stage III EGFR-mutated non-small cell lung cancer treated with chemoradiotherapy: Final analysis of a global real-world study
Lung Cancer
Ahn MJ, Lin SH, Yang CT, Lee JB, Neal JW, Okishio K, Nishino K, Smith D, Rauter M, Jimenez M, Nasirova F, Kim Y
doi: 10.1016/j.lungcan.2025.108748